Validation Of Preference Module Of Experience With Allergic Rhinitis Nasal Sprays Questionnaire (EARNS-Q)

GlaxoSmithKline (GSK)

Status and phase: Completed; Phase 3

Conditions: Rhinitis, Allergic, Perennial

Treatments: Drug: Flunisolide; Drug: Beclomethasone dipropionate

Study type: Interventional

Funder types: Industry

Identifiers

NCT00346775

FFR105693

Details and patient eligibility

About

The Protocol section needs to be updated using the following text "The main goal of the study was to validate the Preference Module of the EARNS-Q and to test the reliability using Treatment Satisfaction Questionnaire for Medicines (TSQM), a validated questionnaire for determining satisfaction among different treatment. The EARNS-Q is divided into 2 modules, an Experience Module and a Preference Module. The Experience Module includes 28 items, fourteen attribute rating items followed by fourteen importance weighing questions. The Preference Module includes the same items along with preference questions related to each item as well as a global preference question.

Enrollment: 97 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Seasonal allergic rhinitis.
• Nasal allergy symptoms during the spring allergy season.

Exclusion criteria

• Prior use of beclomethasone dipropionate or flunisolide.
• Significant concomitant medical conditions.
• Use of corticosteroids.
• Use of allergy and other identified medications during the study.
• Current tobacco use or tobacco use within the past year.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Single Blind